| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2962115 | Journal of Cardiac Failure | 2006 | 6 Pages |
Abstract
Spironolactone prevents the decrease in eNOS in the LV and aorta and improves NO-dependent vasorelaxation, suggesting that one potential mechanism of spironolactone is an improvement in vasoreactivity mediated though an increase in NO.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Hoang M. MD, Bao Q. MD, Trung D. MD, Mohamed A. PhD, Steven MD,